drugset / Trial / NCT02115113
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C virus (HCV), hepatocellular carcinoma (HCC), and short/long-term implications. Then efficacy and safety of a calcineurin inhibitor (CNI)-withdrawal regimen was evaluated in comparison with a CNI-minimization regimen.
Timeline
- Start
- 2014-03-28
- Primary completion
- 2016-09-30
- Completion
- 2016-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 1 mg | Oral |
| Subject | Tacrolimus | Small molecule | — | Oral |
Indications
No indication recorded.